We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much a $1000 Investment in Bruker Made 10 Years Ago Would Be Worth Today
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Bruker (BRKR - Free Report) ten years ago? It may not have been easy to hold on to BRKR for all that time, but if you did, how much would your investment be worth today?
Bruker's Business In-Depth
With that in mind, let's take a look at Bruker's main business drivers.
Billerica, MA-headquartered Bruker Corporation designs and manufactures proprietary life science and materials research systems and associated products that serve multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. Currently, Bruker employs 6,000 individuals who work at 90 locations across the globe. It has direct sales forces employed through North America, Europe, Japan, Asia Pacific and Australia.
Business Segments:
Bruker Scientific Instruments (BSI) Life Science: Within the segment, Bruker reports under two groups: Bruker BioSpin Group (comprising 28.6% of revenues in 2021, up 15.2% from 2020) and Bruker CALID Group (33.9%, up 25.3%).
The Bruker BioSpin comprises the Bruker Magnetic Resonance and Preclinical Imaging divisions, which designs, manufactures and distributes enabling life science tools based on the magnetic resonance technology.
The Bruker CALID comprises the Bruker Daltonics and primarily designs, manufactures and distributes life-science mass spectrometry instruments that can be integrated with other sample preparation or chromatography instruments.
BSI Nano (28.8%, up 25.4%): The Bruker Nano combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions, and designs, manufactures and distributes advanced X-ray instruments to determine the characteristics of matter and the three-dimensional structure of molecules.
Bruker Energy & Supercon Technologies (BEST) (9%, up 18.1%): This segment designs, manufactures and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.
Bottom Line
While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Bruker ten years ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in February 2012 would be worth $4,377.61, or a gain of 337.76%, as of February 28, 2022, according to our calculations. This return excludes dividends but includes price appreciation.
Compare this to the S&P 500's rally of 221.05% and gold's return of 7.47% over the same time frame.
Looking ahead, analysts are expecting more upside for BRKR.
Bruker ended the fourth quarter of 2021 with better-than-expected revenues. The top line was driven by robust revenue growth across all geographies as well as within the BSI and BEST businesses. CALID revenues benefitted from robust growth in life science mass spectrometry and the MALDI Biotyper franchise. Robust bookings and backlog growth in the fourth quarter buoy optimism. Bruker’s financial outlook for 2022 with solid growth projections over 2021 also instills investors’ confidence. However, the year-over-year decline in BioSpin Group revenues does not bode well. The rise in operating costs is concerning. The company is also facing supply chain and logistics delays, raising apprehension. Contraction of adjusted operating margin is another downside. Over the past year, Bruker has underperformed its industry.
Over the past four weeks, shares have rallied 10.03%, and there have been 4 higher earnings estimate revisions in the past two months for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much a $1000 Investment in Bruker Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Bruker (BRKR - Free Report) ten years ago? It may not have been easy to hold on to BRKR for all that time, but if you did, how much would your investment be worth today?
Bruker's Business In-Depth
With that in mind, let's take a look at Bruker's main business drivers.
Billerica, MA-headquartered Bruker Corporation designs and manufactures proprietary life science and materials research systems and associated products that serve multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. Currently, Bruker employs 6,000 individuals who work at 90 locations across the globe. It has direct sales forces employed through North America, Europe, Japan, Asia Pacific and Australia.
Business Segments:
Bruker Scientific Instruments (BSI) Life Science: Within the segment, Bruker reports under two groups: Bruker BioSpin Group (comprising 28.6% of revenues in 2021, up 15.2% from 2020) and Bruker CALID Group (33.9%, up 25.3%).
The Bruker BioSpin comprises the Bruker Magnetic Resonance and Preclinical Imaging divisions, which designs, manufactures and distributes enabling life science tools based on the magnetic resonance technology.
The Bruker CALID comprises the Bruker Daltonics and primarily designs, manufactures and distributes life-science mass spectrometry instruments that can be integrated with other sample preparation or chromatography instruments.
BSI Nano (28.8%, up 25.4%): The Bruker Nano combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions, and designs, manufactures and distributes advanced X-ray instruments to determine the characteristics of matter and the three-dimensional structure of molecules.
Bruker Energy & Supercon Technologies (BEST) (9%, up 18.1%): This segment designs, manufactures and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.
Bottom Line
While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Bruker ten years ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in February 2012 would be worth $4,377.61, or a gain of 337.76%, as of February 28, 2022, according to our calculations. This return excludes dividends but includes price appreciation.
Compare this to the S&P 500's rally of 221.05% and gold's return of 7.47% over the same time frame.
Looking ahead, analysts are expecting more upside for BRKR.
Bruker ended the fourth quarter of 2021 with better-than-expected revenues. The top line was driven by robust revenue growth across all geographies as well as within the BSI and BEST businesses. CALID revenues benefitted from robust growth in life science mass spectrometry and the MALDI Biotyper franchise. Robust bookings and backlog growth in the fourth quarter buoy optimism. Bruker’s financial outlook for 2022 with solid growth projections over 2021 also instills investors’ confidence. However, the year-over-year decline in BioSpin Group revenues does not bode well. The rise in operating costs is concerning. The company is also facing supply chain and logistics delays, raising apprehension. Contraction of adjusted operating margin is another downside. Over the past year, Bruker has underperformed its industry.
Over the past four weeks, shares have rallied 10.03%, and there have been 4 higher earnings estimate revisions in the past two months for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.